SCHEMBL24434614

SCHEMBL24434614

CCc1ccncc1CCc1ccccc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR1A P08908 1/20 0.45
DRD2 P14416 1/20 0.45
ABCB1 P08183 1/20 0.44
ALDH1A1 P00352 1/20 0.43
KDM6B O15054 3/20 0.41
KDM4C Q9H3R0 3/20 0.41
HTT P42858 1/20 0.41
TP53 P04637 1/20 0.40
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40
CYP1A2 P05177 2/20 0.40
CYP3A4 P08684 2/20 0.40
CYP2D6 P10635 2/20 0.40
CYP2C9 P11712 2/20 0.40
CYP2C19 P33261 2/20 0.40
TDP1 Q9NUW8 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
CHRNB2 P17787 1/20 0.40
CHRNA4 P43681 1/20 0.40
HIF1A Q16665 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9589256 0.83 TDP1 (0.45) KDM6BKDM4CTDP1L3MBTL1KDM4D
SCHEMBL9588340 0.83 TDP1 (0.49) KDM6BKDM4CTDP1L3MBTL1KDM4D
SCHEMBL9587804 0.81 TDP1 (0.47) KDM6BKDM4CTDP1L3MBTL1
SCHEMBL9588643 0.81 TDP1 (0.47) KDM6BKDM4CTDP1L3MBTL1
SCHEMBL24434902 0.81 HTR1A (0.42) HTR1ADRD2ABCB1ALDH1A1NPC1
SCHEMBL9589128 0.81 TDP1 (0.47) KDM6BKDM4CTDP1L3MBTL1
SCHEMBL9587577 0.81 TDP1 (0.47) KDM6BKDM4CTDP1L3MBTL1
SCHEMBL25825918 0.81 TDP1 (0.54) HTR1ADRD2ALDH1A1CYP1A2CYP2D6
SCHEMBL6385911 0.80 CYP11B1 (0.51) HTR1ADRD2ABCB1ALDH1A1KDM6B
SCHEMBL6257548 0.79 KDM6B (0.46) ALDH1A1KDM6BKDM4CNPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220153732-A1 PROTEIN SECRETION INHIBITORS ENODIA THERAPEUTICS SAS (FR) 2022-05-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220153732-A1 PROTEIN SECRETION INHIBITORS SEC61B, SEC61A1, SEC61G HTR1A 3598/4885DRD2 4602/4885ABCB1 905/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.